Home
The Department of Biomedicine

News archive for The Department of Biomedicine

This phase IB/II trial is designed to investigate the safety and survival benefits for patients with recurrent glioblastoma with unmethylated MGMT promoter treated with Bortezomib and Temozolomide in a specific schedule.
For the third time, the Faculty of Medicine organized a career day for its PhD candidates. NTNU sent representatives to learn from us.